Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU, Short-Term Results of a Multicenter Trial of GETECCU

  • Aguas, Mariam|||0000-0003-4353-569X
  • Del Hoyo, Javier|||0000-0003-3603-5793
  • Vicente, Raquel|||0000-0002-7605-3534
  • Barreiro de-Acosta, Manuel|||0000-0001-5915-1477
  • Melcarne, Luigi|||0000-0002-9718-9692
  • Hernández Camba, Alejandro|||0000-0002-8653-207X
  • Madero, Lucía
  • Arroyo, María Teresa
  • Sicilia Aladrén, Beatriz|||0000-0002-4495-9358
  • Chaparro, María|||0000-0002-9275-4242
  • Martín-Arranz, María Dolores|||0000-0002-1872-0917
  • Pajares, Ramón|||0000-0003-0549-6036
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Mañosa i Ciria, Míriam|||0000-0002-9051-2581
  • Martinez Tirado, Pilar
  • Chacón, Silvia
  • Tosca, Joan
  • Marín, Sandra
  • Sanroman, Luciano
  • Calvo, Marta
  • Monfort, David
  • Saiz, Empar
  • Zabana, Yamile|||0000-0003-4023-8868
  • Guerra, Iván|||0000-0002-5175-2515
  • Varela, Pilar|||0000-0003-1737-3236
  • Baydal Bertomeu, Virginia
  • Faubel, Raquel|||0000-0002-8716-8003
  • Corsino, Pilar|||0000-0002-3412-8104
  • Porto-Silva, Sol
  • Brunet, Eduard|||0000-0001-8661-0608
  • González, Melodi
  • Gutiérrez Casbas, Ana|||0000-0002-5460-4139
  • Nos, Pilar|||0000-0002-6619-1511
Background: Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to be more efficient. Objective: This study aims to compare the remission time and quality of life of patients with active IBD managed through standard care versus the TECCU (Telemonitoring of Crohn Disease and Ulcerative Colitis) app. Methods: A 2-arm, randomized, multicenter trial with a noninferiority design was conducted across 24 hospitals in Spain. The study included adult patients with IBD who were starting immunosuppressive or biological therapy. Participants were randomized into 2 groups: the telemonitoring group (G_TECCU) and the standard care group (G_Control). The follow-up schedule for the telemonitoring group (G_TECCU) was based on contacts via the TECCU app, while the control group (G_Control) adhered to standard clinical practice, which included in-person visits and telephone calls. In both groups, treatment adjustments were made based on the progression of disease activity and medication adherence, assessed using specific indices and biological markers at each check-up. The primary outcome was the duration of remission after 12 weeks, while secondary outcomes included quality of life, medication adherence, adverse events, and patient satisfaction. Results: Of the 169 patients enrolled, 158 were randomized and 150 were analyzed per protocol: telemonitoring (n=71) and control (n=79). After 12 weeks, the time in clinical remission was not inferior in the telemonitoring group (mean 4.20, SD 3.73 weeks) compared with the control group (mean 4.32, SD 3.28 weeks), with a mean difference between arms of -0.12 weeks (95% CI -1.25 to 1.01; noninferiority P=.02). The mean reduction in C-reactive protein values was -15.40 mg/L (SD 90.15 mg/L; P=.19) in the G_TECCU group and -13.16 mg/L (SD 54.61 mg/L; P=.05) in the G_Control group, with no significant differences between the 2 arms (P=.73). Similarly, the mean improvement in fecal calprotectin levels was 832.3 mg/L (SD 1825.0 mg/L; P=.003) in the G_TECCU group and 1073.5 mg/L (SD 3105.7 mg/L; P=.03) in the G_Control group; however, the differences were not statistically significant (P=.96). Quality of life improved in both groups, with a mean increase in the 9-item Inflammatory Bowel Disease Questionnaire score of 13.44 points (SD 19.1 points; P<.001) in the G_TECCU group and 18.23 points (SD 22.9 points; P=.001) in the G_Control group. Additionally, the proportion of patients who adhered to their medication significantly increased from 35% (25/71) to 68% (48/71) in the G_TECCU group (P=.001) and from 46% (36/79) to 73% (58/79) in the G_Control group (P=.001). The satisfaction rate remained stable at around 90%, although noninferiority was not demonstrated for the secondary outcomes. Conclusions: Telemonitoring patients with active IBD is not inferior to standard care for achieving and maintaining short-term remission. The TECCU app may serve as a viable alternative follow-up tool, pending confirmation of improved health outcomes and cost-effectiveness over the long-term.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Colorimetric assay for the quantitation of iron in yeast

  • Tamarit Sumalla, Jordi
  • Irazusta, Verónica Patricia
  • Moreno Cermeño, Armando J.
  • Ros Salvador, Joaquim
This study was supported by Grants BFU2004-00593/BMC and GEN2001-4707C08-06 from the Ministerio de Ciencia y Tecnología (Spain). V.I. is a recipient of a Ph.D. scholarship from the Generalitat de Catalunya.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Manganese Is the Link between Frataxin and Iron-Sulfur Deficiency in the Yeast Model of Friedreich Ataxia

  • Irazusta, Verónica Patricia
  • Cabiscol Català, Elisa
  • Reverter Branchat, Gemma
  • Ros Salvador, Joaquim
  • Tamarit Sumalla, Jordi
Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin. Proteomic analysis of the mutant yeast model of Friedreich ataxia presented in this paper reveals that these cells display increased amounts of proteins involved in antioxidant defenses, including manganese-superoxide dismutase. This enzyme shows, however, lower activity than that found in wild type cells. Our results indicate that this lack of activity is a consequence of cellular manganese deficiency, because in manganese-supplemented cultures, cell manganese content, and manganese-superoxide dismutase activity were restored. One of the hallmarks of Friedreich ataxia is the decreased activity of iron/sulfur-containing enzymes. The activities of four enzymes of this group (aconitase, glutamate synthase, succinate dehydrogenase, and isopropylmalate dehydratase) have been analyzed for the effects of manganese supplementation. Enzyme activities were recovered by manganese treatment, except for aconitase, for which, a specific interaction with frataxin has been demonstrated previously. Similar results were obtained when cells were grown in iron-limited media suggesting that manganese-superoxide dismutase deficiency is a consequence of iron overload. In conclusion, these data indicate that generalized deficiency of iron-sulfur protein activity could be a consequence of manganese-superoxide dismutase deficiency, and consequently, it opens new strategies for Friedreich ataxia treatment., This work was supported in part by Friedreich Ataxia Research Alliance (Arlington, VA) and Grants BFU2004-00593/BMC and GEN2001-4707C08-06 from the Ministerio de Educación y Ciencia (Spain).
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Major targets of iron-induced protein oxidative damage in frataxin-deficient yeasts are magnesium-binding proteins

  • Irazusta, Verónica Patricia
  • Moreno Cermeño, Armando J.
  • Cabiscol Català, Elisa
  • Ros Salvador, Joaquim
  • Tamarit Sumalla, Jordi
Iron accumulation has been associated with several pathological conditions such as Friedreich ataxia. This human disorder is caused by decreased expression of frataxin. Iron-overload triggers oxidative stress, but the main targets of such stress are not known. In yeast cells lacking the frataxin ortholog YFH1, we have identified a set of 14 carbonylated proteins, which include mitochondrial ATP synthase, phosphoglycerate kinase, pyruvate kinase, and molecular chaperones. Interestingly, most of the target proteins are magnesium- and/or nucleotide-binding proteins. This key feature leads us to postulate that when iron accumulates, chelatable iron replaces magnesium at the corresponding metal-binding site, promoting selective damage to these proteins. Consistent with this hypothesis, in vitro experiments performed with pure pyruvate kinase and phosphoglycerate kinase showed that oxidation of these proteins can be prevented by magnesium and increased by the presence of ATP. Also, chelatable iron, which forms complexes with nucleotides, showed a sevenfold increase in Δyfh1 cells. Moreover, lowering chelatable iron in Δyfh1 cells by desferrioxamine prevented enzyme inactivation. As a general conclusion, we propose that magnesium bound to proteins is replaced by chelatable iron when this metal accumulates. This mechanism explains selective protein oxidation and provides clues for better understanding of iron-overloading pathologies., This work is supported by the Friedreich’s Ataxia Research Alliance (Arlington, VA, USA) and Grants BFU2004-00593/BMC and CSD2007-00020 Consolider- Ingenio 2010 from the Ministerio de Educación y Ciencia (Spain). V.I. is the recipient of a Ph.D. fellowship from the Generalitat de Catalunya.
Repositorio Institucional de la Universidad de Burgos (RIUBU)
Publicación Artículo científico (JournalArticle)

LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus

  • Cobo Vuilleumier, Nadia .
  • Lorenzo, Petra Isabel .
  • García Rodríguez, Noelia .
  • Gracia Herrera-Gómez, Irene de .
  • Fuente Martín, Esther .
  • López Noriega, Livia
  • Mellado Gil, José Manuel .
  • Romero Zerbo, Silvana-Yanina .
  • Baquié, Mathurin .
  • Lachaud, Christian Claude .
  • Stifter, Katja .
  • Perdomo Hernández, Germán M.
  • Bugliani, Marco .
  • Tata, Vincenzo de .
  • Bosco, Domenico .
  • Parnaud, Geraldine .
  • Pozo, David .
  • Hmadcha, Abdelkrim .
  • Florido, Javier P. .
  • Toscano, Miguel G. .
  • Haan, Peter de .
  • Schoonjans, Kristina .
  • Sánchez Palazón, Luis .
  • Marchetti, Piero .
  • Schirmbeck, Reinhold .
  • Martín Montalvo, Alejandro .
  • Meda, Paolo .
  • Soria, Bernat .
  • Bermúdez Silva, Francisco Javier .
  • St-Onge16, Luc .
  • Gauthier, Benoit R. .
Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus., the Juvenile Diabetes Research Foundation (17-2013-372 to B.R.G.), the Consejeria de Salud, Fundacion Publica Andaluza Progreso y Salud, Junta de Andalucia (PI-0727-2010 to B.R.G. and P10CTS6505 to B.S.), Consejeria de Economia, Innovacion y Ciencia (P10.CTS.6359 to B.R.G.), the Ministerio de Economia y Competidividad cofunded by Fondos FEDER (PI10/00871, PI13/00593, and BFU2017-83588-P to B.R.G.; PI14/01015, RD12/0019/0028, and RD16/0011/0034 to B.S.; PI16/00259 to A. H.) and Deutsche Forschungsgemeinschaft (GRK-1789 ´CEMMA´ and DFG SCHI-505/ 6-1 to R.S.). Special thanks to the families of the DiabetesCero Foundation that graciously supported this work (to B.R.G.). A.M.M. is a recipient of a Miguel Servet grant (CP14/ 00105) from the Instituto de Salud Carlos III co-funded by Fondos FEDER whereas E.F. M. is a recipient of a Juan de la Cierva Fellowship. I.G.H.G. is supported by a fellowship from Amarna Therapeutics. In some instances, human islets were procured through the European Consortium for Islet Transplantation funded by Juvenile Diabetes Research Foundation (3-RSC-2016-162-I-X).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications

  • Sánchez-Tejerina, Daniel
  • Llaurado, Arnau
  • Sotoca, Javier
  • Lopez-Diego, Veronica
  • Vidal-Taboada, jose M
  • Salvadó Figueras, Maria
  • Juntas Morales, Raúl
Amyotrophic lateral sclerosis; Biomarker; Prognosis, Esclerosi lateral amiotròfica; Biomarcador; Pronòstic, Esclerosis lateral amiotrófica; Biomarcador; Pronóstico, Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by the degeneration of motor neurons for which effective therapies are lacking. One of the most explored areas of research in ALS is the discovery and validation of biomarkers that can be applied to clinical practice and incorporated into the development of innovative therapies. The study of biomarkers requires an adequate theoretical and operational framework, highlighting the “fit-for-purpose” concept and distinguishing different types of biomarkers based on common terminology. In this review, we aim to discuss the current status of fluid-based prognostic and predictive biomarkers in ALS, with particular emphasis on those that are the most promising ones for clinical trial design and routine clinical practice. Neurofilaments in cerebrospinal fluid and blood are the main prognostic and pharmacodynamic biomarkers. Furthermore, several candidates exist covering various pathological aspects of the disease, such as immune, metabolic and muscle damage markers. Urine has been studied less often and should be explored for its possible advantages. New advances in the knowledge of cryptic exons introduce the possibility of discovering new biomarkers. Collaborative efforts, prospective studies and standardized procedures are needed to validate candidate biomarkers. A combined biomarkers panel can provide a more detailed disease status., This study has been funded by Instituto de Salud Carlos III through the project “PI19/0593” (co-funded by European Regional Development Fund: “A way to make Europe “).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi
  • Turon-Sans, Janina
  • Ximelis, Teresa
  • Aldecoa, Iban
  • Molina-Porcel, Laura
  • Povedano, Mónica
  • Gamez Carbonell, Josep
Proteïna TDP-43; Esclerosi lateral amiotròfica; Demència frontotemporal, Proteína TDP-43; Esclerosis lateral amiotrófica; Demencia frontotemporal, TDP-43 protein; Amyotrophic lateral sclerosis; Frontotemporal dementia, Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer’s disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups., SBE is a recipient of the Rio-Hortega post-residency grant from the Instituto de Salud Carlos III, Spain. This study was partially funded by Fundació Marató de TV3 (grant no. 20141610 to EG and no. 20143710 to RRG) and Fondo Europeo de Desarrollo Regional (FEDER) (PI15/01618 to RRG). AA is funded by Departament de Salut de la Generalitat de Catalunya, Pla estratègic de recerca i innovació en salut (PERIS) 2016–2020 (SLT002/16/00329). JG is recipient of the Instituto de Salud Carlos III-FEDER grants (PI16/01673 and PI19/00593)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Colorimetric assay for the quantitation of iron in yeast

  • Tamarit Sumalla, Jordi
  • Irazusta, Verónica Patricia
  • Moreno Cermeño, Armando J.
  • Ros Salvador, Joaquim
This study was supported by Grants BFU2004-00593/BMC and GEN2001-4707C08-06 from the Ministerio de Ciencia y Tecnología (Spain). V.I. is a recipient of a Ph.D. scholarship from the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Human Microglia-Like Cells Differentiated from Monocytes with GM-CSF and IL-34 Show Phagocytosis of α-Synuclein Aggregates and C/EBPβ-Dependent Proinflammatory Activation

  • Llaves-López, Andrea
  • Micoli, Elia
  • Belmonte Mateos, Carla
  • Aguilar, Gerard
  • Alba, Clara
  • Marsal, Anais
  • Vidal-Taboada, jose M
Cell culture; In vitro model; Microglia, Cultiu cel·lular; Model in vitro; Micròglia, Cultivo celular; Modelo in vitro; Microglía, Microglia, the main resident immune cells in the central nervous system, are implicated in the pathogenesis of various neurological disorders. Much of our knowledge on microglial biology was obtained using rodent microglial cultures. To understand the role of microglia in human disease, reliable in vitro models of human microglia are necessary. Monocyte-derived microglia-like cells (MDMi) are a promising approach. This study aimed to characterize MDMi cells generated from adult human monocytes using granulocyte–macrophage colony-stimulating factor and interleukin-34. To this end, 49 independent cultures of MDMI were prepared, and various methodological and functional studies were performed. We show that with this protocol, adult human monocytes develop into microglia-like cells, a coating is unnecessary, and high cell density seeding is preferable. When compared to monocytes, MDMi upregulate the expression of many, but not all, microglial markers, indicating that, although these cells display a microglia-like phenotype, they cannot be considered bona fide human microglia. At the functional level, MDMi phagocytose α-synuclein aggregates and responds to lipopolysaccharide (LPS) by nuclear translocation of the transcription factor nuclear factor-kappaB (NFkappaB) and the upregulation of proinflammatory genes. Finally, a long-lasting silencing of the transcription factor CCAAT/enhancer protein β (C/EBPβ) was achieved by small interfering RNA, resulting in the subsequent downregulation of proinflammatory genes. This supports the hypothesis that C/EBPβ plays a key role in proinflammatory gene program activation in human microglia. Altogether, this study sheds new light on the properties of MDMi cells and supports these cells as a promising in vitro model for studying adult human microglia–like cells., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was supported by grants PI14/00302 and PI19/00593 from the Instituto de Salud Carlos III (Spain) with joint financing by FEDER funds from the European Union.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Haplotype Analysis of the First A4V-SOD1 Spanish Family: Two Separate Founders or a Single Common Founder?

  • Garcia Rodríguez, Cecilia
  • Vidal Taboada, José Manuel
  • Syriani Casagrande, Enrique
  • Salvadó Figueras, Maria
  • Morales, Miguel
  • Gamez Carbonell, Josep
A4V; SOD1; Esclerosi lateral amiotròfica, A4V; SOD1; Esclerosis lateral amiotrófica, A4V; SOD1; Amyotrophic lateral sclerosis, Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) (fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most common cause of the disease, accounting for around 20% of all families (ALS1) and isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have been reported to date. The possibility of a single founder and separate founders have been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations worldwide. High-throughput single nucleotide polymorphism genotyping studies have suggested two founders for A4V (one for the Amerindian population and another for the European population) although the possibility that the two populations are descended from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them with the population reference panels, to demonstrate that the first A4V Spanish pedigree shared the genetic background reported in the European population., This study has been supported by Instituto de Salud Carlos III (grant numbers PIS-FEDER PI16/01673 and PI19/00593). JG and JV-T are the recipients of grant 2017SGR00939 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Manganese Is the Link between Frataxin and Iron-Sulfur Deficiency in the Yeast Model of Friedreich Ataxia

  • Irazusta, Verónica Patricia
  • Cabiscol Català, Elisa
  • Reverter Branchat, Gemma
  • Ros Salvador, Joaquim
  • Tamarit Sumalla, Jordi
Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin. Proteomic analysis of the mutant yeast model of Friedreich ataxia presented in this paper reveals that these cells display increased amounts of proteins involved in antioxidant defenses, including manganese-superoxide dismutase. This enzyme shows, however, lower activity than that found in wild type cells. Our results indicate that this lack of activity is a consequence of cellular manganese deficiency, because in manganese-supplemented cultures, cell manganese content, and manganese-superoxide dismutase activity were restored. One of the hallmarks of Friedreich ataxia is the decreased activity of iron/sulfur-containing enzymes. The activities of four enzymes of this group (aconitase, glutamate synthase, succinate dehydrogenase, and isopropylmalate dehydratase) have been analyzed for the effects of manganese supplementation. Enzyme activities were recovered by manganese treatment, except for aconitase, for which, a specific interaction with frataxin has been demonstrated previously. Similar results were obtained when cells were grown in iron-limited media suggesting that manganese-superoxide dismutase deficiency is a consequence of iron overload. In conclusion, these data indicate that generalized deficiency of iron-sulfur protein activity could be a consequence of manganese-superoxide dismutase deficiency, and consequently, it opens new strategies for Friedreich ataxia treatment., This work was supported in part by Friedreich Ataxia Research Alliance (Arlington, VA) and Grants BFU2004-00593/BMC and GEN2001-4707C08-06 from the Ministerio de Educación y Ciencia (Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Major targets of iron-induced protein oxidative damage in frataxin-deficient yeasts are magnesium-binding proteins

  • Irazusta, Verónica Patricia
  • Moreno Cermeño, Armando J.
  • Cabiscol Català, Elisa
  • Ros Salvador, Joaquim
  • Tamarit Sumalla, Jordi
Iron accumulation has been associated with several pathological conditions such as Friedreich ataxia. This human disorder is caused by decreased expression of frataxin. Iron-overload triggers oxidative stress, but the main targets of such stress are not known. In yeast cells lacking the frataxin ortholog YFH1, we have identified a set of 14 carbonylated proteins, which include mitochondrial ATP synthase, phosphoglycerate kinase, pyruvate kinase, and molecular chaperones. Interestingly, most of the target proteins are magnesium- and/or nucleotide-binding proteins. This key feature leads us to postulate that when iron accumulates, chelatable iron replaces magnesium at the corresponding metal-binding site, promoting selective damage to these proteins. Consistent with this hypothesis, in vitro experiments performed with pure pyruvate kinase and phosphoglycerate kinase showed that oxidation of these proteins can be prevented by magnesium and increased by the presence of ATP. Also, chelatable iron, which forms complexes with nucleotides, showed a sevenfold increase in Δyfh1 cells. Moreover, lowering chelatable iron in Δyfh1 cells by desferrioxamine prevented enzyme inactivation. As a general conclusion, we propose that magnesium bound to proteins is replaced by chelatable iron when this metal accumulates. This mechanism explains selective protein oxidation and provides clues for better understanding of iron-overloading pathologies., This work is supported by the Friedreich’s Ataxia Research Alliance (Arlington, VA, USA) and Grants BFU2004-00593/BMC and CSD2007-00020 Consolider- Ingenio 2010 from the Ministerio de Educación y Ciencia (Spain). V.I. is the recipient of a Ph.D. fellowship from the Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Haplotype Analysis of the First A4V-SOD1 Spanish Family, Two Separate Founders or a Single Common Founder?

  • Garcia, Cecilia
  • Vidal-Taboada, José Manuel
  • Syriani, Enrique
  • Salvado, María
  • Morales, Miguel
  • Gamez, Josep|||0000-0003-3127-7486
Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) (fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most common cause of the disease, accounting for around 20% of all families (ALS1) and isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have been reported to date. The possibility of a single founder and separate founders have been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations worldwide. High-throughput single nucleotide polymorphism genotyping studies have suggested two founders for A4V (one for the Amerindian population and another for the European population) although the possibility that the two populations are descended from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them with the population reference panels, to demonstrate that the first A4V Spanish pedigree shared the genetic background reported in the European population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis, Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Ximelis, Teresa
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Povedano, Mónica
  • Rubio, Miguel Angel|||0000-0002-0495-6240
  • Gamez, Josep|||0000-0003-3127-7486
  • Cano, Antonio
  • Paré-Curell, Martí|||0000-0002-0627-5350
  • Bajo, Lorena
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Balasa, Mircea|||0000-0002-1795-4228
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Gelpi, Ellen|||0000-0003-2948-4187
Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer's disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy

  • Statland, J.M.|||0000-0003-0790-5315
  • Campbell, C.
  • Desai, Urvi|||0000-0001-5196-7201
  • Karam, C.
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Guptill, J.T.
  • Korngut, L.
  • Genge, A.
  • Tawil, R.N.
  • Elman, Lauren B.
  • Joyce, N.C.
  • Wagner, K.R.
  • Manousakis, Georgios|||0000-0002-8309-9426
  • Amato, A.A.
  • Butterfield, R.J.|||0000-0002-8452-7189
  • Shieh, P.B.|||0000-0001-7145-7663
  • Wicklund, M.
  • Gamez, Josep|||0000-0003-3127-7486
  • Bodkin, C.
  • Pestronk, Alan|||0000-0002-8991-5770
  • Weihl, C.C.
  • Vílchez Padilla, Juan J.
  • Johnson, N.E.|||0000-0002-3917-4257
  • Mathews, K.D.
  • Miller, B.
  • Leneus, A.
  • Fowler, M.
  • van de Rijn, M.
  • Attie, K.M.
Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy without approved therapies. In this study we evaluated whether locally acting ACE-083 could safely increase muscle volume and improve functional outcomes in adults with FSHD. Participants were at least 18 years old and had FSHD1/FSHD2. Part 1 was open label, ascending dose, assessing safety and tolerability (primary objective). Part 2 was randomized, double-blind for 6 months, evaluating ACE-083240 mg/muscle vs placebo injected bilaterally every 3 weeks in the biceps brachii (BB) or tibialis anterior (TA) muscles, followed by 6 months of open label. Magnetic resonance imaging measures included total muscle volume (TMV; primary objective), fat fraction (FF), and contractile muscle volume (CMV). Functional measures included 6-minute walk test, 10-meter walk/run, and 4-stair climb (TA group), and performance of upper limb midlevel/elbow score (BB group). Strength, patient-reported outcomes (PROs), and safety were also evaluated. Parts 1 and 2 enrolled 37 and 58 participants, respectively. Among 55 participants evaluable in Part 2, the least-squares mean (90% confidence interval, analysis of covariance) treatment difference for TMV was 16.4% (9.8%-23.0%) in the BB group (P <.0001) and 9.5% (3.2%-15.9%) in the TA group (P =.01). CMV increased significantly in the BB and TA groups and FF decreased in the TA group. There were no consistent improvements in functional or PRO measures in either group. The most common adverse events were mild or moderate injection-site reactions. Significant increases in TMV with ACE-083 vs placebo did not result in consistent functional or PRO improvements with up to 12 months of treatment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi
  • Turon-Sans, Janina
  • Ximelis, Teresa
  • Aldecoa, Iban
  • Molina-Porcel, Laura
  • Povedano, Mónica
  • Gamez Carbonell, Josep
Proteïna TDP-43; Esclerosi lateral amiotròfica; Demència frontotemporal, Proteína TDP-43; Esclerosis lateral amiotrófica; Demencia frontotemporal, TDP-43 protein; Amyotrophic lateral sclerosis; Frontotemporal dementia, Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer’s disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups., SBE is a recipient of the Rio-Hortega post-residency grant from the Instituto de Salud Carlos III, Spain. This study was partially funded by Fundació Marató de TV3 (grant no. 20141610 to EG and no. 20143710 to RRG) and Fondo Europeo de Desarrollo Regional (FEDER) (PI15/01618 to RRG). AA is funded by Departament de Salut de la Generalitat de Catalunya, Pla estratègic de recerca i innovació en salut (PERIS) 2016–2020 (SLT002/16/00329). JG is recipient of the Instituto de Salud Carlos III-FEDER grants (PI16/01673 and PI19/00593)
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Haplotype Analysis of the First A4V-SOD1 Spanish Family: Two Separate Founders or a Single Common Founder?

  • Garcia Rodríguez, Cecilia
  • Vidal Taboada, José Manuel
  • Syriani Casagrande, Enrique
  • Salvadó Figueras, Maria
  • Morales, Miguel
  • Gamez Carbonell, Josep
A4V; SOD1; Esclerosi lateral amiotròfica, A4V; SOD1; Esclerosis lateral amiotrófica, A4V; SOD1; Amyotrophic lateral sclerosis, Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) (fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most common cause of the disease, accounting for around 20% of all families (ALS1) and isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have been reported to date. The possibility of a single founder and separate founders have been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations worldwide. High-throughput single nucleotide polymorphism genotyping studies have suggested two founders for A4V (one for the Amerindian population and another for the European population) although the possibility that the two populations are descended from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them with the population reference panels, to demonstrate that the first A4V Spanish pedigree shared the genetic background reported in the European population., This study has been supported by Instituto de Salud Carlos III (grant numbers PIS-FEDER PI16/01673 and PI19/00593). JG and JV-T are the recipients of grant 2017SGR00939 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Human Microglia-Like Cells Differentiated from Monocytes with GM-CSF and IL-34 Show Phagocytosis of α-Synuclein Aggregates and C/EBPβ-Dependent Proinflammatory Activation

  • Llaves-López, Andrea
  • Micoli, Elia
  • Belmonte Mateos, Carla
  • Aguilar, Gerard
  • Alba, Clara
  • Marsal, Anais
  • Vidal-Taboada, jose M
Cell culture; In vitro model; Microglia, Cultiu cel·lular; Model in vitro; Micròglia, Cultivo celular; Modelo in vitro; Microglía, Microglia, the main resident immune cells in the central nervous system, are implicated in the pathogenesis of various neurological disorders. Much of our knowledge on microglial biology was obtained using rodent microglial cultures. To understand the role of microglia in human disease, reliable in vitro models of human microglia are necessary. Monocyte-derived microglia-like cells (MDMi) are a promising approach. This study aimed to characterize MDMi cells generated from adult human monocytes using granulocyte–macrophage colony-stimulating factor and interleukin-34. To this end, 49 independent cultures of MDMI were prepared, and various methodological and functional studies were performed. We show that with this protocol, adult human monocytes develop into microglia-like cells, a coating is unnecessary, and high cell density seeding is preferable. When compared to monocytes, MDMi upregulate the expression of many, but not all, microglial markers, indicating that, although these cells display a microglia-like phenotype, they cannot be considered bona fide human microglia. At the functional level, MDMi phagocytose α-synuclein aggregates and responds to lipopolysaccharide (LPS) by nuclear translocation of the transcription factor nuclear factor-kappaB (NFkappaB) and the upregulation of proinflammatory genes. Finally, a long-lasting silencing of the transcription factor CCAAT/enhancer protein β (C/EBPβ) was achieved by small interfering RNA, resulting in the subsequent downregulation of proinflammatory genes. This supports the hypothesis that C/EBPβ plays a key role in proinflammatory gene program activation in human microglia. Altogether, this study sheds new light on the properties of MDMi cells and supports these cells as a promising in vitro model for studying adult human microglia–like cells., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was supported by grants PI14/00302 and PI19/00593 from the Instituto de Salud Carlos III (Spain) with joint financing by FEDER funds from the European Union.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications

  • Sánchez-Tejerina, Daniel
  • Llaurado, Arnau
  • Sotoca, Javier
  • Lopez-Diego, Veronica
  • Vidal-Taboada, jose M
  • Salvadó Figueras, Maria
  • Juntas Morales, Raúl
Amyotrophic lateral sclerosis; Biomarker; Prognosis, Esclerosi lateral amiotròfica; Biomarcador; Pronòstic, Esclerosis lateral amiotrófica; Biomarcador; Pronóstico, Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by the degeneration of motor neurons for which effective therapies are lacking. One of the most explored areas of research in ALS is the discovery and validation of biomarkers that can be applied to clinical practice and incorporated into the development of innovative therapies. The study of biomarkers requires an adequate theoretical and operational framework, highlighting the “fit-for-purpose” concept and distinguishing different types of biomarkers based on common terminology. In this review, we aim to discuss the current status of fluid-based prognostic and predictive biomarkers in ALS, with particular emphasis on those that are the most promising ones for clinical trial design and routine clinical practice. Neurofilaments in cerebrospinal fluid and blood are the main prognostic and pharmacodynamic biomarkers. Furthermore, several candidates exist covering various pathological aspects of the disease, such as immune, metabolic and muscle damage markers. Urine has been studied less often and should be explored for its possible advantages. New advances in the knowledge of cryptic exons introduce the possibility of discovering new biomarkers. Collaborative efforts, prospective studies and standardized procedures are needed to validate candidate biomarkers. A combined biomarkers panel can provide a more detailed disease status., This study has been funded by Instituto de Salud Carlos III through the project “PI19/0593” (co-funded by European Regional Development Fund: “A way to make Europe “).